Mitozolomide

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Mitozolomide
Mitozolomide.svg
Clinical data
ATC code none
Identifiers
CAS Number 85622-95-3 YesY
PubChem (CID) 71766
ChemSpider 64805 N
UNII E3U7286V3W N
ChEMBL CHEMBL435951 N
Chemical and physical data
Formula C7H7ClN6O2
Molar mass 242.622 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Mitozolomide (INN) is an antineoplastic. It is an imidazotetrazine derivative.

Development of mitozolomide was discontinued during Phase II clinical trials after it was found to cause severe and unpredictable bone marrow suppression.[1] Temozolomide, which has been in clinical use since 1999, is a less toxic analogue of mitozolomide.[2]

References[edit]

  1. ^ Fairbairn LJ, Chinnasamy N, Lashford LS, Chinnasamy D, Rafferty JA (February 2000). "Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide" (PDF). Cancer Gene Ther. 7 (2): 233–9. doi:10.1038/sj.cgt.7700120. PMID 10770631. 
  2. ^ Newlands ES, Blackledge GR, Slack JA, et al. (February 1992). "Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)". Br J Cancer. 65 (2): 287–91. doi:10.1038/bjc.1992.57. PMC 1977719Freely accessible. PMID 1739631.